ADAM: Innovative Project for 3D Bioprinting of Organic Bones’ Structures
Time：2019-06-12 From：
ADAM sets new milestone in medical technology by launching the 3D bioprinting of organic bone structures. ADAM has started passing the regulatory requirements to begin preclinical trials.
ADAM is a biotechnical initiative, cofounded by Kwambio (3D printing experts) and WeFund Ventures (an early stage venture fund). It is based in BioCT Innovation Commons (Groton, Conn.), and has already gained support from Applied Medical and Techstars.
The core of ADAM’s innovative approach is the combination of new materials for 3D printing. One is a modified biopolymer based on polycaprolactone with the addition of hydroxyapatite, which has high strength and good bioresorbability. Another is a ceramic bioglass based on hydroxyapatite and borosilicate glass, which is able to react with bone tissue to effectively connect with the implant and stimulate osteogenesis.
Defects in bones that do not bear direct physical exertion and perform only protective and skeletal functions (bones of the skull, upper and lower jaws), could be treated with ceramic bioglass implants, while modified biopolymer would be used for defects in tubular bones. Materials have been successfully tested at Lund University (Sweden).
“One hundred twenty-thousand people are in the waiting list for organ transplants in the U.S.A. Over 1 million people have the same needs all over the world. New technologies aim to solve this problem, and ADAM is the first ever opportunity to print organic bones. The key reason for us to launch this project is to help people save their lives,” said Volodymyr Usov, CEO at ADAM.
One of the planned next steps of the project is to develop a cloud-based digital platform, for creating a 3D model of a body using computer tomography files.
“The global 3D bioprinting market is rapidly growing. According to researchers, it is going to develop very intensively up to 2024, achieving more than $2.5 billion. We do believe in the potential of the team, which previously has launched successful 3D printing projects that already gained a lot of attention. And we hope that ADAM will bring this endeavor for innovations to the next level,” commented Denys Gurak, partner at WeFund Ventures and board chairman at ADAM.
Kwambio is an additive manufacturing company and a developer of products with implementations in a variety of fields such as spare part and product design, aerospace, and heavy industries. Stanley Black&Decker is among key partners of Kwambio. The list of customers includes General Electric, Airbus, and others. Kwambio has also collaborated with NASA and Tesla. The company is located in New York, N.Y.; London; and Odessa, Ukraine.
Wefund Ventures is an early-stage venture capital firm focused on promising projects across IT, biotech and internet sectors.
[News Resource]https://www.odtmag.com/
ADAM is a biotechnical initiative, cofounded by Kwambio (3D printing experts) and WeFund Ventures (an early stage venture fund). It is based in BioCT Innovation Commons (Groton, Conn.), and has already gained support from Applied Medical and Techstars.
The core of ADAM’s innovative approach is the combination of new materials for 3D printing. One is a modified biopolymer based on polycaprolactone with the addition of hydroxyapatite, which has high strength and good bioresorbability. Another is a ceramic bioglass based on hydroxyapatite and borosilicate glass, which is able to react with bone tissue to effectively connect with the implant and stimulate osteogenesis.
Defects in bones that do not bear direct physical exertion and perform only protective and skeletal functions (bones of the skull, upper and lower jaws), could be treated with ceramic bioglass implants, while modified biopolymer would be used for defects in tubular bones. Materials have been successfully tested at Lund University (Sweden).
“One hundred twenty-thousand people are in the waiting list for organ transplants in the U.S.A. Over 1 million people have the same needs all over the world. New technologies aim to solve this problem, and ADAM is the first ever opportunity to print organic bones. The key reason for us to launch this project is to help people save their lives,” said Volodymyr Usov, CEO at ADAM.
One of the planned next steps of the project is to develop a cloud-based digital platform, for creating a 3D model of a body using computer tomography files.
“The global 3D bioprinting market is rapidly growing. According to researchers, it is going to develop very intensively up to 2024, achieving more than $2.5 billion. We do believe in the potential of the team, which previously has launched successful 3D printing projects that already gained a lot of attention. And we hope that ADAM will bring this endeavor for innovations to the next level,” commented Denys Gurak, partner at WeFund Ventures and board chairman at ADAM.
Kwambio is an additive manufacturing company and a developer of products with implementations in a variety of fields such as spare part and product design, aerospace, and heavy industries. Stanley Black&Decker is among key partners of Kwambio. The list of customers includes General Electric, Airbus, and others. Kwambio has also collaborated with NASA and Tesla. The company is located in New York, N.Y.; London; and Odessa, Ukraine.
Wefund Ventures is an early-stage venture capital firm focused on promising projects across IT, biotech and internet sectors.
[News Resource]https://www.odtmag.com/